AI spots silent heart failure in diabetics before symptoms start
NCT ID NCT06593314
First seen May 18, 2026 · Last updated Jun 21, 2026 · Updated 10 times
Summary
This study tests whether an AI-powered tool can help doctors detect a type of heart failure (HFpEF) that often goes undiagnosed in people with type 2 diabetes. Researchers will use echocardiogram results and an AI algorithm to flag patients at risk, then alert their doctors. The goal is to see if these alerts lead to more prescriptions of medications that can prevent heart failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75235, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI algorithm (EchoGo) and clinical decision support alerts
What this could lead to
If successful, this could help doctors identify hidden heart failure earlier in diabetes patients and start preventive medications sooner.
What could go wrong
This is a pragmatic trial testing a decision-support tool, not a new drug. The AI may not change prescribing habits, and results may not apply to all clinics.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.